Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Follicular 3Lymphoma 3Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Zollinger-Ellison Syndrome 1Uterine Cervical Neoplasms 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Multiple Myeloma 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Kidney Neoplasms 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Blast Crisis 1Adenoma, Islet Cell 1

Interventions

Omeprazole 2Lansoprazole 2Esomeprazole 2pazopanib 1cixutumumab 1Temozolomide 1Streptozocin 1Salts 1Pantoprazole 1Octreotide 1Interferons 1Fluorouracil 1Everolimus 1Doxorubicin 1Dexlansoprazole 1Clopidogrel 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Zollinger-Ellison Syndrome × Interferons × Clear all
NCT00001228 2017-07-02

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled

Adenoma, Islet Cell, Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡